301060 Shanghai Labway Clinical Laboratory
- 10.48
- -0.30-2.78%
Shanghai Labway Clinical Laboratory News
Lanwei Medical (301060.SZ): The testing programs provided include eugenics and childbearing tests, prenatal screening, etc.
Gelonghui, May 10 | Lanwei Medical (301060.SZ) said on the investor interactive platform that the testing services provided by the company cover molecular tests, biochemical tests, immunological tests, basic clinical tests (clinical body fluids and blood tests), and physico-chemical tests. The service customers include medical institutions such as maternal and child health hospitals, and the testing items provided include eugenics and prenatal screening.
Lanwei Medical (301060.SZ) announced first-quarter results, net profit of 1.071,700 yuan, a decrease of 95% year-on-year
Lanwei Medical (301060.SZ) released its report for the first quarter of 2024. The company achieved revenue during the reporting period...
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
Lanwei Medical (301060.SZ): A total cost of 15.3867 million yuan to buy back 1.1612,000 shares
Gelonghui, April 2, 丨 Lan Wei Medical (301060.SZ) announced that as of March 31, 2024, the company had repurchased a total of 1.1612 million shares through the Shenzhen Stock Exchange stock trading system, accounting for 0.29% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 9.69 yuan/share, and the total transaction amount was RMB 15.3867 million (excluding transaction fees).
A-share afternoon review: Shanghai index rose 0.45%, leading the AIGC concept, medical services, and automotive sectors
Major A-share indices had mixed ups and downs. As of the midday close, the Shanghai Index rose 0.45% to 3076.67 points, the Shenzhen Stock Exchange Index fell 0.05%, and the GEM Index fell 0.16%.
Lanwei Medical (301060.SZ): A total cost of 14.9986 million yuan to buy back 0.28% of the shares
Gelonghui, Feb. 2: Lanwei Medical (301060.SZ) announced that as of January 31, 2024, the company had repurchased 1,121,200 shares of the company's shares through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 0.28% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 12.75 yuan/share, and the total transaction amount was RMB 14,998,563.00.
Express News | Lanwei Medical: Expected net loss of 110 million yuan to 165 million yuan in 2023, turning profit into loss
Lanwei Medical (301060.SZ): A total cost of 10.254,200 yuan to buy back 751,500 shares
Gelonghui, January 4, 丨 Lan Wei Medical (301060.SZ) announced that as of December 31, 2023, the company had repurchased 751,500 shares of the company's shares through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 0.19% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 12.78 yuan/share, and the total transaction amount was RMB 10.254,200 (excluding transaction fees).
Lanwei Medical (301060.SZ): Not involved in the development and sale of synthetic protein products
Gelonghui December 28 丨 An investor asked Lanwei Medical (301060.SZ) on the investor interactive platform, “Does your company have biotechnological reserves of synthetic proteins? Or is there any product development and sales in this area?” The company replied that the company is not involved in the development and sale of synthetic protein products for the time being.
Sun Linjie, director of Lan Wei Medical (301060.SZ), did not reduce his holdings at the end of the period
Lan Wei Medical (301060.SZ) announced that company director Sun Linjie did not reduce his holdings of the company's shares during the current holdings reduction plan period...
Lanwei Medicine (301060.SZ): Gene-edited drugs are currently not related to the company's testing business
On December 12, Gelonghui Medical (301060.SZ) stated on the investor interactive platform that gene-editing drugs are currently not related to the company's testing business, and whether expansion is necessary requires more extensive and in-depth research.
Lanwei Medicine (301060.SZ): The company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing
On December 12, Gelonghui Medical (301060.SZ) stated on the investor interactive platform on December 12 that the company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing to meet customer needs.
Lanwei Medical (30100.SZ): The initial repurchase of 65,000 shares involved 914,900 yuan
Gelonghui Medical (30100.SZ) announced on December 8, 2023/12, that as of December 8, 2023, the company has repurchased the company's shares through centralized bidding transactions for the first time through a special securities repurchase account. The number of shares repurchased this time is 65,000 shares, accounting for 0.0162% of the company's current total share capital. The maximum transaction price is 14.23 yuan/share, the minimum transaction price is 13.95 yuan/share, and the transaction amount is 9148.57 million yuan (excluding transaction fees).
Lanwei Medical (301060.SZ): No share repurchase has been implemented yet
Gelonghui on December 5 | Lanwei Medical (301060.SZ) announced that as of November 30, 2023, the company has opened a special repurchase securities account at the Shenzhen branch of China Securities Registration and Settlement Co., Ltd., and the company has not yet implemented a share repurchase.
The genetic testing sector increased, and Lanwei Medical surged 13%
Gelonghui, November 22 | The A-share genetic testing sector has risen, Lanwei Medicine has surged 13%, Berry Gene has been linked to 3, and International Medicine, Yao Ji Technology, and Huada Zhizao have followed suit slightly.
Lanwei Medical (30100.SZ) plans to spend 15 million yuan to 30 million yuan to buy back the company's shares
Lanwei Medical (301060.SZ) issued an announcement that the company plans to use its own capital through the trading department of the Shenzhen Stock Exchange...
Lanwei Medical (30100.SZ) released the first three quarter results, with a net loss of 881,000 yuan
Lanwei Medical (301060.SZ) released its report for the third quarter of 2023, achieving revenue of 12 in the first three quarters...
[Instant Analysis of BT Financial Report] Lanwei Medical's 2023 Interim Report: Key Metrics such as Net Assets, Balance Ratio, and Gross Margin
Lanwei Medical (stock code: 301060) is a leading comprehensive service provider in the laboratory and diagnosis industry. It provides third-party medical testing and pathological diagnosis services, as well as in vitro diagnostic products and other professional technical support from well-known domestic and foreign brands. After years of development, the company has established a systematic, large-scale and networked service system. It is committed to becoming an effective complement to public medical institutions, providing comprehensive testing and diagnosis programs and specialized services for medical institutions. Now let's take a look at the financial data for Lanwei Medical's 2023 interim report. First, we see that the total closing balance of the company's assets is 32
Hailan Group, the majority shareholder of Lan Wei Medical (301060.SZ), reduced its holdings by a total of 3.622 million shares until the end of the holdings reduction period
Lan Wei Medical (301060.SZ) issued an announcement. The shareholder of the company holds more than 5% of the shares, Hailan Group Co., Ltd. (hereinafter...
Lan Wei Medical (301060.SZ): Net loss of 1.82 million yuan in the first half of the year was converted to loss year-on-year
GLONGHUI, August 30 | Lan Wei Medical (301060.SZ) released its semi-annual report. Operating income was 838 million yuan, down 59.34% year on year, net loss of 1.82 million yuan, year on year before loss, net loss of 1.276 million yuan, net loss of 12.076 million yuan, year-on-year loss, and basic earnings per share of -0.0046 yuan.
Analysis
Price Target
No Data
